The MHRA’s updated medicine broker registry establishes three critical safeguards for healthcare institutions sourcing pharmaceutical products. First, all legitimate brokers must maintain active registration with the regulatory agency, making the public registry an essential verification tool before partnering with any intermediary. Second, the transparent listing of company names, registration details, and addresses enables rapid authentication of broker credentials.
Third, this oversight system functions as part of a broader anti-counterfeiting strategy that protects the integrity of medicines from manufacturer to patient. Healthcare providers should routinely cross-reference potential brokers against the current MHRA registry before engaging their services. This practical verification step represents a frontline defense against counterfeit medicines and supply chain compromises. By leveraging the public registry, institutions strengthen their procurement protocols and reinforce commitment to patient safety through evidence-based supply chain management.
Read the full article on GMJ Newsroom.
Was this article helpful?
